DaVita Inc. (DVA) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
Revenue Growth Metrics
Revenue Breakdown (FY 2024)
DVA's revenue distribution by segment and geography for fiscal year 2024
By Product/Segment
DVA Revenue Analysis (2014–2025)
As of March 2, 2026, DaVita Inc. (DVA) generated trailing twelve-month (TTM) revenue of $13.64 billion, reflecting solid growth of +9.9% year-over-year. The most recent quarter (Q4 2025) recorded $3.62 billion in revenue, up 5.8% sequentially.
Looking at the longer-term picture, DVA's 5-year compound annual growth rate (CAGR) stands at +3.4%, indicating moderate growth over time. The company achieved its highest annual revenue of $14.75 billion in 2016.
Revenue diversification analysis shows DVA's business is primarily driven by U S Dialysis And Related Lab Services (100%). With over half of revenue concentrated in U S Dialysis And Related Lab Services, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including FMS (+1.5% YoY), TOI (+21.7% YoY), and CCM (-22.5% YoY), DVA has underperformed the peer group in terms of revenue growth. Compare DVA vs FMS →
Peer Comparison
Compare DVA's revenue metrics with industry peers
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| DVACurrent | $13.6B | +9.9% | +3.4% | 14.7% | |
| FMS | $19.6B | +1.5% | +1.9% | 9.3% | |
| TOI | $393M | +21.7% | +20.4% | -15.3% | |
| CCM | $384M | -22.5% | +14.1% | -138.6% |
Historical Revenue Data
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $13.64B | +6.5% | $3.68B | 27.0% | $2.01B | 14.7% |
| 2024 | $12.82B | +5.6% | $4.22B | 32.9% | $2.09B | 16.3% |
| 2023 | $12.14B | +4.6% | $3.82B | 31.5% | $1.60B | 13.2% |
| 2022 | $11.61B | -0.1% | $3.40B | 29.3% | $1.34B | 11.5% |
| 2021 | $11.62B | +0.6% | $3.65B | 31.4% | $1.80B | 15.5% |
| 2020 | $11.55B | +1.4% | $3.56B | 30.8% | $1.69B | 14.7% |
| 2019 | $11.39B | -0.1% | $3.47B | 30.5% | $1.64B | 14.4% |
| 2018 | $11.40B | +4.9% | $3.21B | 28.1% | $1.53B | 13.4% |
| 2017 | $10.88B | -26.2% | $3.24B | 29.8% | $1.81B | 16.7% |
| 2016 | $14.75B | +7.0% | $3.28B | 22.2% | $2.03B | 13.8% |
See DVA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs DVA Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare DVA vs AGIO
See how DVA stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is DVA's revenue growth accelerating or slowing?
DVA maintains +9.9% revenue growth, in line with its 5-year CAGR of +3.4%. TTM revenue stands at $13.6B. Growth rate remains consistent with historical average.
What is DVA's long-term revenue growth rate?
DaVita Inc.'s 5-year revenue CAGR of +3.4% reflects the sustained expansion pattern. Current YoY growth of +9.9% is near this long-term average.
How is DVA's revenue distributed by segment?
DVA reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.